Skip to Main Content

Author Details

Caryn Bern
University of California San Francisco School of Medicine
1989
204
56
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37853514Chagas Disease Diagnostic Practices at Four Major Hospital Systems in California and Texas.J Infect Dis2024
37805935Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk HIV in the United States.Clin Infect Dis2024
36853034Concordance of Results by Three Chagas Disease Antibody Assays in U.S. Clinical Specimens.J Clin Microbiol2023
36853062Evaluation of InBios Chagas Detect Fast, a Novel Enzyme-Linked Immunosorbent Assay for the Detection of Anti-Trypanosoma cruzi Antibodies.J Clin Microbiol2023
34134129Congenital Chagas disease in Santa Cruz Department, Bolivia, is dominated by Trypanosoma cruzi lineage V.Trans R Soc Trop Med Hyg2022
35647262Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain: <i>Win, Miranda</i> prediction of Chagas cardiomyopathy.Int J Cardiol Heart Vasc2022
35731040Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States.Emerg Infect Dis2022
36052609A Composite Recombinant Salivary Proteins Biomarker for Phlebotomus argentipes Provides a Surveillance Tool Postelimination of Visceral Leishmaniasis in India.J Infect Dis2022
34918158Enteropathogen Changes After Rotavirus Vaccine Scale-up.Pediatrics2022
35180299Screening for Chagas Disease Should Be Included in Entry-to-Care Testing for At-Risk People With Human Immunodeficiency Virus (HIV) Living in the United States.Clin Infect Dis2022
34623435Recommendations for Screening and Diagnosis of Chagas Disease in the United States.J Infect Dis2022
34240175Deep Sequencing to Detect Diversity of Trypanosoma cruzi Infection in Patients Coinfected With Human Immunodeficiency Virus and Chagas Disease.J Infect Dis2022
32667981The Immunoglobulin M-Shed Acute Phase Antigen (SAPA)-test for the Early Diagnosis of Congenital Chagas Disease in the Time of the Elimination Goal of Mother-to-Child Transmission.Clin Infect Dis2021
33768013Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.Front Cell Infect Microbiol2021
33762363Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease.J Clin Microbiol2021
33842396Development and Evaluation of Active Case Detection Methods to Support Visceral Leishmaniasis Elimination in India.Front Cell Infect Microbiol2021
33842395Optimizing Village-Level Targeting of Active Case Detection to Support Visceral Leishmaniasis Elimination in India.Front Cell Infect Microbiol2021
33501951Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity.Clin Infect Dis2021
33884277Evaluation of 2 Lateral Flow Rapid Tests in the Diagnosis of Chagas Disease in the Washington Metropolitan Area.Open Forum Infect Dis2021
34398818HIV and Chagas Disease: An Evaluation of the Use of Real-Time Quantitative Polymerase Chain Reaction to Measure Levels of Trypanosoma cruzi Parasitemia in HIV Patients in Cochabamba, Bolivia.Am J Trop Med Hyg2021
34842854Chagas Disease in People with HIV: A Narrative Review.Trop Med Infect Dis2021
34019089Variation in SARS-CoV-2 Infection Risk and Socioeconomic Disadvantage Among a Mayan-Latinx Population in Oakland, California.JAMA Netw Open2021
34013283Significant and sustained decrease in non-SARS-CoV-2 respiratory viral infections during COVID-19 public health interventions.medRxiv2021
34114721Improving houses in the Bolivian Chaco increases effectiveness of residual insecticide spraying against infestation with Triatoma infestans, vector of Chagas disease.Trop Med Int Health2021
34134775Indoor residual spraying practices against Triatoma infestans in the Bolivian Chaco: contributing factors to suboptimal insecticide delivery to treated households.Parasit Vectors2021
33399201Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.Am J Clin Pathol2021
33451361Visceral leishmaniasis outbreaks in Bihar: community-level investigations in the context of elimination of kala-azar as a public health problem.Parasit Vectors2021
32766826Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.Clin Infect Dis2021
32511497Test performance evaluation of SARS-CoV-2 serological assays.medRxiv2020
33079934Outdoor Residual Insecticide Spraying (ODRS), a New Approach for the Control of the Exophilic Vectors of Human Visceral Leishmaniasis: Phlebotomus orientalis in East Africa.PLoS Negl Trop Dis2020
33043286Norovirus-specific immunoglobulin A in breast milk for protection against norovirus-associated diarrhea among infants.EClinicalMedicine2020
33258933A Cluster-based, Spatial-sampling Method for Assessing Household Healthcare Utilization Patterns in Resource-limited Settings.Clin Infect Dis2020
33258932Spatial Heterogeneity of Enteric Fever in 2 Diverse Communities in Nepal.Clin Infect Dis2020
32687498Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.PLoS Negl Trop Dis2020
32855547Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.Nat Biotechnol2020
32163175Evaluation of matrix effects and prolonged storage on Trypanosoma cruzi serology in blood donor specimens.Transfusion2020
30357373Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.Clin Infect Dis2019
31776135Chagas Disease in the United States: a Public Health Approach.Clin Microbiol Rev2019
30252099Trypomastigote Excretory Secretory Antigen Blot Is Associated With Trypanosoma cruzi Load and Detects Congenital T. cruzi Infection in Neonates, Using Anti-Shed Acute Phase Antigen Immunoglobulin M.J Infect Dis2019
31357060Chagas disease in the Bolivian Chaco: Persistent transmission indicated by childhood seroscreening study.Int J Infect Dis2019
31557162Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.PLoS Negl Trop Dis2019
31525195Effect of insecticide-treated bed nets on visceral leishmaniasis incidence in Bangladesh. A retrospective cohort analysis.PLoS Negl Trop Dis2019
31511333Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens.J Clin Microbiol2019
31059501Hindgut microbiota in laboratory-reared and wild Triatoma infestans.PLoS Negl Trop Dis2019
30633743Improved DNA extraction technique from clot for the diagnosis of Chagas disease.PLoS Negl Trop Dis2019
28961918High Rates of Enteric Fever Diagnosis and Lower Burden of Culture-Confirmed Disease in Peri-urban and Rural Nepal.J Infect Dis2018
30095485Congenital Chagas disease: current diagnostics, limitations and future perspectives.Curr Opin Infect Dis2018
30296295The role of case proximity in transmission of visceral leishmaniasis in a highly endemic village in Bangladesh.PLoS Negl Trop Dis2018
30346949Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.PLoS Negl Trop Dis2018
30354432Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association.Circulation2018
  • 1 - 50 of 204

Recommended Authors

Universidade do Estado do Amazonas
Career Start Year 2013
Number of shared co-authors 1
Instituto Nacional de Infectologia Evandro Chagas Fiocruz
Career Start Year 2007
Number of shared co-authors 1
Stanford University
Career Start Year 2007
Number of shared co-authors 0
Tulane University
Career Start Year 2007
Number of shared co-authors 1
University of North Carolina at Chapel Hill
Career Start Year 2006
Number of shared co-authors 1
University of North Carolina School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Federal University of Mato Grosso do Sul
Career Start Year 2001
Number of shared co-authors 1
Career Start Year 2001
Number of shared co-authors 0
University of Maryland
Career Start Year 2000
Number of shared co-authors 0
National Institutes of Health Intramural Research Program
Career Start Year 1995
Number of shared co-authors 2
London School of Hygiene & Tropical Medicine
Career Start Year 1995
Number of shared co-authors 0
Oslo University Hospital
Career Start Year 1994
Number of shared co-authors 0
University of California davis
Career Start Year 1993
Number of shared co-authors 0
Oak Crest Institute of Science
Career Start Year 1992
Number of shared co-authors 0
and the Institute of Social and Preventive Medicine, University of Bern
Career Start Year 1992
Number of shared co-authors 1
University of Science
Career Start Year 1991
Number of shared co-authors 0
Yale University School of Medicine
Career Start Year 1989
Number of shared co-authors 2
Department of Geography & Emerging Pathogens Institute, University of Florida
Career Start Year 1987
Number of shared co-authors 0
University of Liverpool
Career Start Year 1987
Number of shared co-authors 0
Hospital Clinico Universitario de Valladolid
Career Start Year 1985
Number of shared co-authors 0
Instituto Goncalo Moniz, Yale School of Public Health
Career Start Year 1983
Number of shared co-authors 2
School of Public Health, Yale University
Career Start Year 1982
Number of shared co-authors 1
Global Health Institute, University of Antwerp
Career Start Year 1982
Number of shared co-authors 0
University of California at San Francisco
Career Start Year 1979
Number of shared co-authors 3
Italian Ministry of Health
Career Start Year 1977
Number of shared co-authors 0
Graduate School of Public Health, University of Pittsburghgrid.21925.3d
Career Start Year 1976
Number of shared co-authors 0
London School of Hygiene & Tropical Medicine
Career Start Year 1976
Number of shared co-authors 0
University of Virginia
Career Start Year 1973
Number of shared co-authors 0
University of California berkeley
Career Start Year 1971
Number of shared co-authors 4
National Institute of Biomedical Research (INRB)
Career Start Year 1971
Number of shared co-authors 3

Collaborators

University of California San Francisco School of Medicine
Co-authored papers 15
University of North Carolina at Chapel Hill
Co-authored papers 11
Scientific Services
Co-authored papers 8
Gladstone-UCSF Institute of Genomic Immunology
Co-authored papers 4
University of California San Francisco
Co-authored papers 4
Stanford University
Co-authored papers 3
The Salk Institute for Biological Studies
Co-authored papers 3
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
University of California San Francisco
Co-authored papers 3
Massachusetts General Hospital
Co-authored papers 3
University of California san francisco
Co-authored papers 3
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 2
Weill Institute for Neurosciences, University of California-San Francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
University of California-San Francisco
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
University of Chicago
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
San Francisco General Hospital, University of California
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Gladstone-UCSF Institute of Genomic Immunology
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Barcelona Institute for Global Health, Hospital Clinic, University of Barcelona
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 2